TRTravis D. Richardson

Travis D. Richardson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Travis D. Richardson has a total of 210 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The High Road Is Clear

    by Bharat Narasimhan, Travis D. Richardson

  • Open Access

    Optimal pace timing for left bundle branch area pacing with or without an additional LV lead: results from the CSPOT study

    by Robert D Schaller, Paul Foley, Badrinathan Chandrasekaran, Jonathan Lyne, Marek JastrzęBski, Pugazhendhi Vijayaraman, Gaurav A Upadhyay, Rafał Gardas, Travis Richardson, D’ANne Kudlik, et al.

    Aims: This study aimed to determine optimal atrioventricular (AV) timing for left bundle branch area pacing (LBBAP) and optimal AV and interventricular (VV) timing for LBBAP optimized cardiac resynchronization therapy (LOT-CRT) to enhance the benefit of conduction system pacing. Methods and results: Acute measurements of LV dP/dtmax and QRS duration were collected during sweeps of AV and VV delays during paired comparison of LBBAP, LOT-CRT, and biventricular pacing (BVP) in 48 CRT-indicated patients. Optimal AV delays were selected as the vertex of a parabolic model fit to the AV sweep results, obtained independently for LV dP/dtmax and QRS duration. LBBAP, LOT-CRT, and BVP were similarly sensitive to the choice of AV delay, and 60 ms deviations from optimal AV delay resulted in an approximately 30% reduction in the haemodynamic benefits of resynchronization. Based upon LV dP/dtmax measurements, the average optimal paced AV (PAV) for LBBAP (152 ms) was significantly shorter than that for LOT-CRT (171 ms, P < 0.01) or BVP (167 ms, P = 0.01). Based upon QRS duration, the average optimal PAV for LBBAP (164 ms) was similar to that for LOT-CRT (160 ms, P = 0.52) or BVP (165 ms, P = 0.95). For each resynchronization modality, a linear regression between the patient's measured intrinsic AV conduction and their optimal AV delay provided a patient-specific AV delay, resulting in improved AV selection compared to applying a fixed AV delay to all patients. Finally, simultaneous activation (VV = 0) was best for both LOT-CRT and BVP. Conclusion: LBBAP, LOT-CRT, and BVP are similarly sensitive to AV-timing. Optimal AV delay is linearly related to intrinsic AV for each resynchronization modality. For LOT-CRT and BVP, simultaneous biventricular activation is best on average. Clinical Trial Registration information: https://clinicaltrials.gov/study/NCT04905290

  • Open Access

    Intravascular Lithotripsy to Facilitate Extraction of Very Old Cardiac Implantable Electronic Devices Leads

    by Jamie Kowal, Travis Richardson, George H. Crossley

    Background: One of the challenges encountered when extracting transvenous leads with long dwell times is the presence of dense calcifications encasing the leads. This is the most likely reason for failure to advance a laser extraction sheath. The Shockwave intravascular lithotripsy (IVL) device is an angioplasty balloon that delivers intravascular lithotripsy and fractures calcified lesions in the vasculature, approved for use in coronary and arterial angioplasty. It has also been reported as an adjunctive tool in transvenous lead extraction. Objective: To report the Vanderbilt University Medical Center experience using Shockwave(r) Lithotripsy in the extraction of very old leads. Methods: We report procedural outcomes in this retrospective single‐center series of 24 patients in whom IVL was performed for pretreatment before lead extraction. To use the shockwave balloon, one must have venous access along the path of the leads. In some cases, there was venous access, and in others, a lower‐risk lead was extracted first to allow for the passage of the Shockwave balloon. After IVL pretreatment, leads were extracted using conventional laser and, when necessary, mechanical tools. Results: Forty‐nine total leads were extracted, with a median of 2 leads per patient and median dwell time of 16 years with a range of 4–36 years. All transvenous leads were successfully removed, and there were no significant complications. An excimer laser system (Philips, Inc.) was utilized for extraction in all cases, with a median sheath size of 14 Fr. Despite long dwell times, mechanical extraction tools were only required in 6 (12%) of the leads. Conclusion: Our experience contributes to the growing body of data supporting the use of Shockwave IVL as an adjunctive measure during extraction of calcified leads with long dwell time.


  • Ultra-Low Cryoablation for Scar-Related VT Ablation: Results From the US Early Feasibility Study

    by J. Peter Weiss, Vivek Y. Reddy, Harikrishna Tandri, Travis D. Richardson, Edward P. Gerstenfeld, William G. Stevenson, Nabil Jubran, Ilya Grigorov, Roderick Tung

    BACKGROUND: A limitation of ablation for scar-related ventricular tachycardia (VT) is insufficient lesion depth to address nonendocardial substrate. Ultra-low temperature cryoablation (ULTC) at −196°C has been shown to create transmural lesions in preclinical models. Early human studies in Europe have shown safety and efficacy. METHODS: An EFS (Early Feasibility Study) was designed in collaboration with the Food and Drug Administration as a prospective, nonrandomized evaluation of the acute safety and effectiveness of ULTC ablation for scar-related VT. RESULTS: Twenty patients (age 63±14 years; 5% women; LVEF 36±13%; 45% ischemic and 55% nonischemic) underwent VT ablation with ULTC from September to December 2023 at 4 clinical sites. Ablation strategies included substrate modification during sinus rhythm, as well as activation and entrainment mapping when hemodynamics permitted. Mean ULTC lesions were 9.9±3.6, with a total freeze duration of 47±22 minutes. Noninducibility of the targeted VTs was observed in 13 of 14 patients with inducibility tested both pre- and postablation. There were no procedural strokes, tamponades, or deaths. One suspected cardiac perforation without tamponade was conservatively managed. One patient was excluded from the follow-up efficacy analysis due to RF use, and another lacked postacute follow-up due to death from heart failure 1 month post-procedure. Among surviving per-protocol patients, 23.7±4.3 weeks of freedom from VT and implantable cardioverter defibrillator shock were 61.1% (11/18) and 83.3% (15/18), respectively. CONCLUSIONS: In a US EFS, ULTC therapy was safe and effective for the treatment of scar-related VT. The EFS design, in collaboration with the Food and Drug Administration, represents an important initiative to accelerate the evaluation of new medical technologies in the United States. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05675865.


  • Open Access

    Role of concomitant endomyocardial biopsy in non-ischemic cardiomyopathy with ventricular arrhythmias

    by Daisuke Togashi, Yumi Katsume, Shunsuke Uetake, Salah H. Alahwany, William G. Stevenson, Harikrishna S. Tandri, Arvindh N. Kanagasundram, Travis D. Richardson

    Background: In patients with non-ischemic cardiomyopathy (NICM) presenting with ventricular arrhythmias (VAs), the diagnostic yield and clinical significance of routine endomyocardial biopsy (EMB) remain unclear. This study aimed to evaluate the diagnostic utility of EMB with electrophysiological procedures in patients with NICM. Methods: We enrolled 37 consecutive patients with NICM complicated by VAs who underwent EMB during electrophysiological procedures. Clinical history, imaging data, and genetic testing results were collected, and changes in diagnosis based on EMB findings were assessed. Results: The median age was 61 years, and 35 of 37 patients (94.6%) were male. The most common arrhythmia was sustained VT in 27 patients (73.0%), followed by frequent PVCs in 6 (16.2%) and non-sustained VT in 4 (10.8%). Twenty-nine patients (78.4%) underwent catheter ablation, while eight (21.6%) underwent device implantation. EMB identified cardiac amyloidosis in 3 patients (8.1%) via Congo red staining, while the remaining 34 (91.9%) showed nonspecific fibrosis. No complications occurred during EMB. Among the 11 patients (29.7%) who underwent positron emission tomography/computed tomography (PET-CT), six (54.5%) were diagnosed with cardiac sarcoidosis. Genetic testing was performed in 23 patients (62.2%), revealing pathogenic TTN mutations in 2 (8.7%) and an RYR2 mutation (4.3%) consistent with catecholaminergic polymorphic VT. Cardiac MRI was performed in 29 patients (78.4%), with late gadolinium enhancement observed in 2 patients (6.9%) with suspected myocarditis, 1 (3.4%) with suspected sarcoidosis, and 2 (6.9%) with dilated cardiomyopathy. Furthermore, 2 patients (6.9%) showed right ventricular dysfunction with wall motion abnormalities, consistent with arrhythmogenic right ventricular cardiomyopathy. Conclusion: EMB can be safely performed during electrophysiological procedures and may aid diagnosis in selected cases, particularly cardiac amyloidosis. However, PET-CT demonstrated greater overall diagnostic utility.

  • Open Access

    Safety and Efficacy of the Novel OmniaSecure Defibrillation Lead Through Long-Term Follow-Up: Final Results From the LEADR Trial

    by George H Crossley, Prashanthan Sanders, Bert Hansky, Paolo De Filippo, Maully J Shah, Surinder Kaur Khelae, Travis D Richardson, François Philippon, John S Zakaib, Tessa Geelen, et al.

    BACKGROUND: The LEADR (Lead Evaluation for Defibrillation and Reliability) trial evaluated the small-diameter (4.7F), lumenless, integrated bipolar OmniaSecure defibrillation lead. The trial exceeded primary safety and efficacy objective thresholds, demonstrating favorable efficacy at implant and a low rate of complications. Three-year term outcomes of the LEADR trial assessing the OmniaSecure lead are reported here. METHODS: The LEADR trial is a prospective, multicenter, single-arm clinical trial. Patients with an indication for de novo implantable cardioverter defibrillator/cardiac resynchronization therapy defibrillator were implanted with the OmniaSecure lead in standard right ventricle locations and followed at prespecified intervals. The lead was evaluated for safety, efficacy, and reliability through final follow-up. RESULTS: There were 643/657 patients (97.9%) successfully implanted with the OmniaSecure lead with a mean follow-up of 32.4±9.1 months (26% female, 61.9±12.9 years). Pacing capture threshold, pacing impedance, and R-wave amplitudes remained stable throughout. There was a 96.5% freedom from major study lead-related complications at 3 years. At 3 years, 22.3% of patients received appropriate therapies, that is, shock and antitachycardia pacing, with a 75.4% antitachycardia pacing efficacy. Inappropriate shock rate was 2.7% and 5.9% at 1 and 3 years, respectively. CONCLUSIONS: The final results of the LEADR trial demonstrated 3-year term safety, efficacy, and reliability of the OmniaSecure lead, emphasizing the potential utility of this lead in a wide variety of patients.


  • Open Access

    Outcomes of Ventricular Tachycardia Catheter Ablation in Pediatric Arrhythmogenic Right Ventricular Cardiomyopathy

    by Salah H. Alahwany, Shunsuke Uetake, Juan Jiménez-Jáimez, Eva Cabrera-Borrego, Aarti Dalal, Prince J. Kannankeril, M. Benjamin Shoemaker, Daisuke Togashi, Yumi Katsume, Travis D. Richardson, et al.

    BACKGROUND: Radiofrequency catheter ablation (RFCA) of ventricular tachycardia (VT) in arrhythmogenic right ventricular cardiomyopathy is safe and reduces ventricular arrhythmia burden. Previous studies included adult patients, and data on pediatric patients are scarce. The objective of our study was to report on the safety and efficacy of RFCA in pediatric arrhythmogenic right ventricular cardiomyopathy. METHODS: Fifteen patients who fulfilled the 2010 arrhythmogenic right ventricular cardiomyopathy task force criteria, clinically presented before the age of 18, and underwent VT RFCA procedures at ≤21 years old were included. Baseline characteristics, genotypic and phenotypic data, and ablation outcomes were collected. RESULTS: The mean age at symptom onset was 15.5±1.6 years, and at the index procedure was 18.1±2 years, with 73% of the patients being male. Pathogenic mutation in desmosomal genes was detected in 87%. First presentation symptoms included palpitations (33%), syncope (27%), sustained VT (27%), and sudden cardiac arrest (13%). ECG repolarization abnormalities were present in 93% and 40% were reported to be athletes. In the index RFCA procedure, sustained monomorphic VT was induced in 60%. Electroanatomic mapping showed 100% basal RV epicardial substrate and 54% endocardial low voltage/scar. Repeat VT ablation was required in 80% over a mean follow-up of 16.4 months. The median number of procedures was 2 (interquartile range, 2–4), with sustained VT-free survival of 73% over a mean follow-up duration of 21.4 months. No acute periprocedural complications occurred. Bilateral cardiac sympathetic denervation due to recurrent ventricular arrhythmia was performed in 27%. Eventually, 2 patients (13%) developed advanced heart failure and underwent heart transplantation. CONCLUSIONS: Pediatric arrhythmogenic right ventricular cardiomyopathy RFCA is safe, but early recurrences are common, requiring repeat ablations and sometimes bilateral cardiac sympathetic denervation. The substrate is mostly epicardial with preserved endocardial voltage. VT free survival is 73% after multiple procedures. Progressive heart failure requiring transplantation occurred in 13% within 2 decades of initial presentation.


  • Open Access

    Intravascular Lithotripsy to Facilitate Extraction of Very Old CIED Leads

    by Jamie Kowal, Travis Richardson, George H. Crossley

    Background: One of the challenges encountered when extracting transvenous leads with long dwell times is the presence of dense calcifications encasing the leads. This is the most likely reason for failure to advance a laser extraction sheath. The Shockwave™ intravascular lithotripsy (IVL) device is an angioplasty balloon that delivers intravascular lithotripsy and fractures calcified lesions in the vasculature, approved for use in coronary and arterial angioplasty. It has also been reported as an adjunctive tool in transvenous lead extraction. Objective: To report the Vanderbilt University Medical Center experience using Shockwave Lithotripsy in the extraction of very old leads. Methods: We report procedural outcomes in this retrospective single-center series of twenty-four patients in whom IVL was performed for pretreatment prior to lead extraction. To use the shockwave balloon, one must have venous access along the path of the leads. In some cases, there was venous access and in others a newer lead was extracted first to allow for the passage of the Shockwave balloon. After IVL pre-treatment, leads were extracted using conventional laser and, when necessary, mechanical tools. Results: Forty-nine total leads were extracted with a median of 2 leads per patient and median dwell time of 16 years with a range of 4-36 years. All transvenous leads were successfully removed and there were no significant complications. An excimer laser system (Philips, Inc.) was utilized for extraction in all cases with a median sheath size of 14 Fr. Despite long dwell times, mechanical extraction tools were only required in 6 (12%) of the leads. Conclusion: Our experience contributes to the growing body of data supporting the use of Shockwave IVL as an adjunctive measure during extraction of calcified leads with long dwell time.

  • 2-Hydroxybenzylamine for Treatment of Atrial Fibrillation: A First-in-Human Clinical Pilot Trial

    by Zachary T. Yoneda, Matthew O’NEill, Diane M. Crawford, Mingfang Ao, Lili Sun, Majd A. El-Harasis, Lisa Pitchford, John A. Rathmacher, Jay Montgomery, Sharon T. Shen, et al.

    BACKGROUND: Inflammation is a common mechanism for atrial fibrillation (AF). 2-Hydroxybenzylamine (2-HOBA) is a novel therapeutic that scavenges isolevuglandins—a downstream mediator of inflammation and oxidative stress. 2-HOBA is safe and reduces AF in mice, prompting a first-in-human pilot clinical trial. METHODS: Participants were enrolled and randomized 1:1 to placebo or 2-HOBA (750 mg p.o. TID) 3 days before a planned AF ablation. Participants were monitored for 28 days after their ablation for recurrence of AF as detected by smartwatch single-lead ECG recordings. Blood was collected at the time of ablation for measurement of isolevuglandin levels. The study drug was stopped at 28 days. A 12-month extended follow-up period was used to monitor for any residual effect of the study drug on AF recurrence. RESULTS: 2-HOBA increased the risk of AF recurrence in the postablation population (odds ratio, 3.65 [95% CI, 1.31–10.16]; P =0.013) after prespecified adjustment for potential confounders. This increased risk of recurrence remained despite post hoc adjustment for other clinical risk factors. There was no difference in isolevuglandin levels between the 2-HOBA and placebo groups. After the study drug was stopped, there was no difference in AF recurrence between the 2-HOBA and placebo groups during the 12-month extended follow-up. CONCLUSIONS: 2-HOBA was associated with a higher risk of AF recurrence when tested early after AF ablation. This result was unexpected based on preclinical data, but paradoxical associations with AF have been previously reported for other drugs that target inflammation and oxidative stress pathways, such as omega-3 fatty acids. The mechanisms for AF immediately following ablation may be different from AF that occurs under other conditions, and the generalizability of these results to all forms of AF remains unknown.


  • Open Access

    Fascicular and Papillary Muscle Arrhythmias in the Structurally Normal Heart

    by Travis D Richardson, Roy M John

    Arrhythmias originating from the specialised cardiac conduction system and papillary muscles can occur in both structurally normal and diseased hearts. Conduction system associated arrhythmias include bundle branch re-entry, fascicular re-entry, non-re-entrant fascicular ventricular tachycardia and idiopathic ventricular fibrillation. Each type of arrhythmia requires a unique diagnostic and therapeutic approach. The papillary muscles may also be a source of ventricular arrhythmias. Ablation of papillary muscle associated arrhythmias may be difficult due to the complexities of mapping, structural abnormalities and potentially the deep location of arrhythmia foci. Tools, such as intracardiac echocardiography, can be valuable.